NCT06835400尚未招募3 期
An Open-Label, Randomized, Two-stage Study to Determine Dose Optimization, Safety, and Noninferiority of Oral Paclitaxel + Encequidar Compared to IV Paclitaxel in Subjects With HER2 Negative Metastatic Breast Cancer
Health Hope Pharma0 个研究点目标入组 340 人开始时间: 2025年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 340
- 主要终点
- Stage 1: Confirmed Tumor Response
研究概览
简要总结
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •≥18 years of age
- •Histologically or cytologically confirmed HER2 negative breast cancer for whom IV paclitaxel monotherapy has been recommended.
- •HER2 negative per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guideline. Subjects can be estrogen receptor/progesterone receptor (ER/PR) positive or negative per ASCO CAP guideline, but ER/PR and HER2 receptor status must be known.
- •Metastatic breast cancer with target lesions measurable by CT scan per RECIST v1.1 criteria confirmed by BICR
- •Adequate hematologic status as demonstrated by not requiring granulocyte colony stimulating factor (G CSF) or transfusion support within 30 days prior to randomization to achieve the following at screening:
- •Absolute neutrophil count (ANC) ≥1500/mm3
- •Platelet count ≥100,000/mm3
- •Hemoglobin ≥9 g/dL
- •Adequate liver function as demonstrated by:
- •Total bilirubin ≤upper limit of normal (ULN) unless the subject has Gilbert's disease, for which bilirubin must be ≤2.0 × ULN
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 × ULN
- •Adequate renal function as demonstrated by estimated glomerular filtration rate (eGFR) ≥60 mL/min
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy at least 6 months, in the judgment of the Investigator
- •Female subjects must be postmenopausal (≥12 months without menses) or surgically sterile (ie, by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or must be using effective contraception (ie, non-hormonal intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.
- •Women of childbearing potential must have a negative screening serum pregnancy test and urine test within 4 days prior to start of dosing in the study and not be breast feeding.
- •Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of investigational product (IP).
排除标准
- •Not recovered to ≤grade 1 toxicity from previous anticancer treatments or previous investigational product (IP) except alopecia
- •QTcF interval ≥470 msec at baseline
- •Relapsed less than 6 months following treatment with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease
- •Known active central nervous system metastasis, including leptomeningeal involvement
- •Currently receiving other medications intended for the treatment of their malignancy
- •Received other IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer
- •Received biologics or monoclonal antibodies intended for the treatment of their malignancy within 30 days of the first study dosing day
- •Received radiation therapy within 2 weeks prior to signing informed consent or radiation therapy is planned within 6 months from the time of signing informed consent
- •Taking a medication known to be a moderate or strong cytochrome P450 (CYP) 3A4 inhibitor or inducer or neurokinin-1 receptor antagonist (NK-1) inhibitor within 14 days prior to start of dosing in the study
- •Taking a medication known to be a moderate or strong CYP2C8 inhibitor or inducer within 14 days prior to start of dosing in the study
- •Taking an oral medication with a narrow therapeutic index known to be a P-glycoprotein (P-gp) substrate within 24 hours prior to start of dosing in the study
- •Taking a medication known to be a P-gp inhibitor or inducer within 14 days prior to start of dosing in the study
- •Taking a medication known to be an organic anion transporting polypeptide 1B1/3 (OATP1B1/3) inhibitor
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements
- •Major surgery to the upper GI tract, inability to take oral medication, or have a history of GI disease or other medical condition that, in the opinion of the Investigator may interfere with oral drug absorption
- •History of significant hypersensitivity-type reaction to paclitaxel or Cremophor EL that would contraindicate the use of IV paclitaxel
- •Known allergic reaction or intolerance to contrast media
- •Documented history of true systemic allergic reaction to 3 or more medications
- •Active hepatitis B (as evidenced by being HBsAg positive) or active hepatitis C (HCV-RNA positive) or cirrhosis of the liver
- •Known HIV infection
- •The Investigator believes that participation in this study would not be acceptable
研究组 & 干预措施
Stage 1: Oral Paclitaxel 165 mg/m2 + Encequidar
Experimental
A minimum of 20 subjects per group will be centrally randomized 1:1 to Oral Paclitaxel 165 mg/m2 + Encequidar 3 weeks of a 4-week cycle (3/4) or Oral Paclitaxel 205 mg/m2 (3/4) + Encequidar.
干预措施: Paclitaxel Capsule (Drug)
Stage 1: Oral Paclitaxel 165 mg/m2 + Encequidar
Experimental
A minimum of 20 subjects per group will be centrally randomized 1:1 to Oral Paclitaxel 165 mg/m2 + Encequidar 3 weeks of a 4-week cycle (3/4) or Oral Paclitaxel 205 mg/m2 (3/4) + Encequidar.
干预措施: Encequidar tablet (Drug)
Stage 1: Oral Paclitaxel 205 mg/m2 + Encequidar
Experimental
A minimum of 20 subjects per group will be centrally randomized 1:1 to Oral Paclitaxel 165 mg/m2 + Encequidar 3 weeks of a 4-week cycle (3/4) or Oral Paclitaxel 205 mg/m2 (3/4) + Encequidar.
干预措施: Paclitaxel Capsule (Drug)
Stage 1: Oral Paclitaxel 205 mg/m2 + Encequidar
Experimental
A minimum of 20 subjects per group will be centrally randomized 1:1 to Oral Paclitaxel 165 mg/m2 + Encequidar 3 weeks of a 4-week cycle (3/4) or Oral Paclitaxel 205 mg/m2 (3/4) + Encequidar.
干预措施: Encequidar tablet (Drug)
Stage 2: Oral Paclitaxel + Encequidar
Experimental
干预措施: Paclitaxel Capsule (Drug)
Stage 2: Oral Paclitaxel + Encequidar
Experimental
干预措施: Encequidar tablet (Drug)
Stage 2: IV Paclitaxel
Active Comparator
干预措施: IV Paclitaxel (Drug)
结局指标
主要结局
Stage 1: Confirmed Tumor Response
时间窗: 6 months
Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria
Stage 2: Confirmed Tumor Response
时间窗: 1 Year
Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaEUCTR2016-001402-41-HUGilead Sciences, Inc144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaMedDRA version: 20.0Level: HLTClassification code 10017812Term: Gastric neoplasms malignantSystem Organ Class: 100000004856EUCTR2016-001402-41-ITGILEAD SCIENCES INCORPORATED144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaEUCTR2016-001402-41-BEGilead Sciences, Inc144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaMedDRA version: 20.0Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001402-41-DEGilead Sciences, Inc120
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaEUCTR2016-001402-41-ESGilead Sciences, Inc120